Syndromes of disseminated intravascular coagulation in obstetrics, pregnancy, and gynecology: Objective criteria for diagnosis and management

Hematology/Oncology Clinics of North America

Volumn 14, Issue 5, 2000, Pages 999-1044

  Bick, Rodger L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ANTIPLASMIN; AMINOCAPROIC ACID; ANTITHROMBIN; ANTITHROMBIN III; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR; CREATININE; D DIMER; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; FIBRINOPEPTIDE A; FRESH FROZEN PLASMA; HEPARIN; HEPARIN COFACTOR; LACTATE DEHYDROGENASE; LOW MOLECULAR WEIGHT HEPARIN; PLASMIN; PROSTACYCLIN; PROTHROMBIN; THROMBIN; THROMBIN ANTITHROMBIN COMPLEX; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID;

AMNION FLUID EMBOLISM; BLOOD COMPONENT THERAPY; DISSEMINATED INTRAVASCULAR CLOTTING; ECLAMPSIA; GYNECOLOGIC CANCER; HELLP SYNDROME; HEMOSTASIS; HUMAN; INTRAVASCULAR HEMOLYSIS; MEDICAL DECISION MAKING; OBSTETRICS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RESPIRATORY FAILURE; REVIEW; SEPTICEMIA; SHOCK LUNG; SOLUTIO PLACENTAE; THROMBOSIS; VIREMIA;

EID: 0033828129     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70169-6     Document Type: Article

References (247)

1. Meningococcemia associated with intravascular coagulation
2. Amniotic fluid embolism: A review
3. Hemorrhagic disorders following amniotic fluid embolism
4. Disseminated intravascular coagulation: Experience in a major cancer center
5. The behavior of alpha-2-plasmin inhibitor in fibrinolyric states
6. The histological diagnosis of amnioric fluid embolism
7. Evaluation of the soluble fibrin monomer complexes and other coagulation parameters in obstetric patients
8. Evaluation of plasminogen and other fibrinolytic parameters in the amniotic fluid [letter]
9. Clinical aspects of disseminated intravascular coagulation: A clinician's point of view
10. Soluble fibrin complexes
11. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative aging study
12. The fibrinolytic system in amniotic fluid embolism
13. Fibrin derivitives, plasma hemoglobin and glomerular fibrin deposition in experimental intra-vascular coagulation
14. An objective study of alternative methods of heparin administration
15. Disseminated intravascular coagulation: Objective criteria for diagnosis and management
16. Disseminated intravascular coagulation: Pathophysiological mechanisms and manifestations
17. Disseminated intravascular coagulation: Objective laboratory diagnostic criteria and guidelines for management
18. Disseminated intravascular coagulation
19. Disseminated intravascular coagulation: Objective criteria for clinical and laboratory diagnosis and assessment of therapeutic response
20. Syndromes of disseminated intravascular coagulation
21. Disseminated intravascular coagulation: Clinical and pathophysiological mechanisms and manifestations
22. Disseminated intravascular coagulation: Objective clinical and laboratory diagnosis, treatment and assessment of therapeutic response
23. Disseminated intravascular coagulation
24. Alterations of hemostasis associated with malignancy: Etiology, pathophysiology, diagnosis and management
25. Alterations of hemostasis associated with malignancy
26. Alterations of hemostasis in malignancy
27. Disseminated intravascular coagulation and related syndromes
28. Disseminated intravascular coagulation: A clinical review
29. Disseminated intravascular coagulation
30. Disseminated intravascular coagulation
31. Disseminated intravascular coagulation and related syndromes. A review
32. Basic mechanisms of hemostasis pertaining to DIC
33. Physiology of hemostasis
34. Coagulation abnormalities in malignancy
35. The clinical significance of fibrinogen degradation products
36. Acquired platelet function defects
37. Clinical hemostasis practice: The major impact of laboratory automation
38. Antithrombin (AT-III) as a diagnostic aid in disseminated intravascular coagulation
39. Hemostasis abnormalities associated with prosthetic devices and organ transplantation
40. Clinical relevance of antithrombin III
41. A clinical comparison of chromogenic fluorometric and natural (fibrinogen) substrates for determination of antithrombin-III
42. Diagnostic efficacy of the D-dimer assay in DIC and related disorders
43. Disseminated intravascular coagulation
44. Clinical implications of molecular markers in hemostasis and thrombosis
45. Disseminated intravascular coagulation and blood component therapy
46. Thrombosis and hemorrhage in oncology patients
47. Physiology of hemostasis
48. The mechanism of pulmonary damage following traumatic shock
49. Morphologic diagnosis of disseminated intravascular coagulation: Histologic, histochemical and electron-microscopic studies
50. Reticulo-endotheliale clearance intravascaler. Fibrinmonere in der milz
51. D-dimers, thrombin antithrombin complexes and prothrombin fragments 1 + 2: Diagnostic value in clinically suspected deep vein thrombosis
52. Coagulation and fibrinolytic systems in pre-eclampsia and eclampsia
53. Disseminated fibrin-thromboembolism among neonates dying within 48 hours of birth
54. Ethanol gelation, a rapid screening test for intravascular coagulation
55. Vascular injury to the kidney
56. Multicentric evaluation of a new assay for prothrombin fragment F 1 + 2 determination
57. The production of schistocytes by fibrin strands (a scanning electron microscope study)
58. Microangiopathic hemolytic anemia: Mechanisms of red-cell fragmentation
59. Clinical aspects and therapy of amniotic fluid embolism. Illustration based on a case report
60. Pulmonary embolism of paraneoplastic origin
61. Increased prothrombin fragment 1 + 2 in Type I diabetic patients
62. Selection of patients with malignant ascites for a peritoneovenous shunt
63. A review of eclampsia in Melbourne: 1978-1992
64. Use of peptidyl-4-methoxy-2-naphthylamides to assay plasmin
65. Mechanism of endotoxin interaction with leukocytes
66. Identification and some properties of a new fast-acting plasmin inhibitor in human plasma
67. Induction of tumor factor expression in human monocyte/endothelium cocultures
68. Changes in the blood coagulation system associated with septicemia
69. Amniotic fluid embolism
70. Disseminated intravascular coagulation in septicemia caused by beta-hemolytic streptococci
71. Fibrinopeptide-A in plasma of normal subjects and patients with disseminated intravascular coagulation and systemic lupus erythematosis
72. Amniotic fluid embolism in trial of labor. A case report
73. The HELLP syndrome. Notes on its pathogenesis and treatment
74. Amniotic fluid embolism and isolated disseminated intravascular coagulation
75. Comparative studies of blood coagulation and platelet aggregation in patients with cancer and non-malignant disease
76. Labor complications of the HELLP syndrome without any predictive factors
77. Measurements of markers of activated coagulation in antithrombin III deficient patients
78. Fibrinopeptide-A and beta-thromboglobulin levels in pre-eclampsia and hypertensive pregnancy
79. The role of blood platelets in the precipitation of soluble fibrin endotoxin
80. Blood coagulation and intravascular hemolysis
81. A comparative evaluation of ELISA's for D-dimer and related fibrin(ogen) degradation products
82. Measurement of cross-linked fibrin degradation products - An immunoassay using monoclonal antibodies
83. Expression of tissue factor and interleukin-1 beta in a novel rabbit model of disseminated intravascular coagulation induced by carrageenan and lipopolysaccharide
84. A study of the procoagulant properties of amniotic fluid and their correlation with the lecithin/sphingomyelin ratio
85. Molecular markers of hemostatic activation: Implications in the diagnosis of thrombosis, vascular and cardiovascular disorders
86. Laboratory evaluation of antithrombin III: A critical overview of currently available methods for antithrombin III measurements
87. Treatment of disseminated intravascular coagulation
88. Maternal mortality in Sweden: 1955-1974
89. The proteolysis of flbrinogen by plasmin: The identification of thrombin-clottable fibrinogen derivatives which polymerize abnormally
90. A molecular model of plasmic degradation of cross-linked fibrin
91. Issues of thrombosis and hemorrhagic events in patients with cancer
92. Virus infection and blood coagulation
93. Cytokines, soluble thrombomodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome
94. Cytokines and plasminogen activator inhibitor-1 in post-trauma disseminated intravascular coagulation: Relationship to multiple organ dysfunction
95. Amniotic fluid embolism: Decreased mortality in a population-based study
96. Bleeding and intravascular dotting in malignancy: A review
97. The amniotic infection syndrome
98. Thrombosis with epsilon-amino-caproic acid therapy
99. Acute promyelocytic leukemia. A model for understanding the role of the malignant cells in hemostasis
100. Pulmonary embolism by amniotic fluid: Report of three cases with a new diagnostic procedure
101. A comparative study of precipitation and paracoagulation by protamine sulfate and ethanol gelation tests
102. Detection of intravascular coagulation by protamine sulfate and ethanol gelation tests
103. Molecular aspects of defibrination in a reptilase-treated case of 'dead-fetus syndrome'
104. Plasma exchange in a patient with postpartum HELLP syndrome
105. Acute respiratory distress syndrome and disseminated intravascular coagulation
106. Disseminated intravascular coagulation with the peritoneovenous shunt
107. Studies on the structure and function of alpha-2-macroglobulin and C1 inactivator
108. Alpha-2-plasmin inhibitor and alpha-2-macroglobulin-plasmin complexes in plasma
109. Parallel determinations of FDP and fibrin monomers with various methods
110. Severe acquired antithrombin III deficiency in relation to hepatic and renal insufficiency and intrauterine fetal death in late pregnancy
111. The appearance of schistocytes in the peripheral blood in correlation to degree of disseminated intravascular coagulation
112. Thrombin enhances monocyte secretion of tumor necrosis factor and interleukin-1 by two distinct mechanisms
113. Endothelin-1 as an aggravating factor of disseminated intravascular coagulation associated with malignant neoplasms
114. HELLP: A cry for laboratory assistance: A comprehensive review of the HELLP syndrome highlighting the role of the laboratory
115. Amniotic fluid embolism following blunt abdominal trauma in pregnancy
116. The clinical use of antithrombin III
117. The Hageman factor dependent pathways of coagulation, fibrinolysis, and kinin generation
118. Heterogeneity of human platelets. VI. Correlation of platelet function with platelet volume
119. Expression of endothelin-1 in amniotic fluid embolism and possible pathophysiological mechanism
120. Histological diagnosis of amniotic fluid embolism by monoclonal antibody TKH-2 that recognizes NeuAc alpha 2-6GaINAc epitope
121. Interaction of fibrinogen degradation products with platelets
122. An evaluation of the euglobulin method for the determination of fibrinolysis
123. The nature of the hemorrhagic disorder accompanying hemolytic transfusion reactions in man
124. Disseminated intravascular coagulation
125. Cerebrovascular diseases in pregnancy and puerperium
126. A study of the role of hemolysis in the hemostatic defect of transfusion reactions
127. Pathophysiology clinical manifestations and therapy of consumptive coagulopathy
128. Corticosteroids and the generalized Schwartzman reaction. Mechanisms of sensitization in the rabbit
129. Disseminated intravascular coagulation: A complication of chemotherapy in acute promyelocytic leukemia
130. The defibrination syndrome
131. Disseminated intravascular coagulation: Complication of LeVeen peritoneovenous shunts
132. A clinicopathologic study of fourteen cases of amniotic fluid embolism
133. Amniotic fluid embolism
134. Products of fibrin(ogen) proteolysis
135. Immunohistochemical identification of syncytiotrophoblastic cells and megakaryocytes in pulmonary vessels in a fatal case of amniotic fluid embolism
136. Detection of serum fibrinogen and fibrin degradation products: Comparison of six techniques using purified products and application in clinical studies
137. High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physico-chemical and immunological characterization
138. 2-terminal amino disulfide knot'
139. Twelve steps to optimal management of HELLP syndrome
140. Development of hirudin as an antithrombotic agent
141. Stroke in pregnancy and the puerperium
142. Pathologic anatomy of the lungs following shock and trauma
143. Comparison between plasma levels of β-thromboglobulin and platelet factor 4 in various diseases
144. Monoclonal antibodies to fibrinogen-fibrin degradation products which contain D-domain
145. Antithrombin concentrate in the management of patients with acute fatty liver of pregnancy
146. Alterations in the blood coagulation system induced by bacterial endotoxin I: In vitro (generalized Schwartzman reaction)
147. Disseminated intravascular coagulation in virus diseases
148. An electron microscope study of the effects of bacterial endotoxin on the blood-vascular system
149. Mechanisms of thrombosis of the microcirculation
150. Thrombolytic therapy and fibrinolytic inhibitors
151. A study of the possible correlation of euglobulin lysis time and dilute blood clot lysis time in the determination of fibrinolytic activity
152. Automation in coagulation testing: Clinical applications
153. Clinical approach to a patient with suspected DIC
154. Critical analysis of hemostasis disorders in the course of eclampsia. Report of 106 cases
155. Amniotic fluid embolism
156. Hemodynamic action of vaso-pressor and vaso-depressor agents in endotoxin shock
157. Pathophysiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways
158. Pathophysiology of generalized intravascular coagulation
159. Precipitation of ancrod-induced soluble fibrin by aprotinin and norepinephrine
160. The molecular structure of fibrinogen
161. A comparative study of four methods for detecting fibrinogen degradation products in patients with various diseases
162. Sudden maternal deaths from amniotic fluid embolism
163. Platelet interaction with polymerizing fibrin
164. Local fibrinolysis as a mechanism for haemorrhage
165. Dexamethasone-facilitated postponement of delivery of an extremely preterm pregnancy complicated by the syndrome of hemolysis, elevated liver enzymes, and low platelets
166. Serological and immunohistochemical diagnosis of amniotic fluid embolism
167. Plasma levels of soluble E-selectin in patients with disseminated intravascular coagulation
168. Plasma levels of granulocyte elastase-alpha 1-proteinase inhibitor complex in patients with disseminated intravascular coagulation: Pathophysiologic implications
169. Coagulopathy in disseminated intravascular coagulation due to abdominal sepsis: Determination of prothrombin fragment 1 + 2 and other markers
170. A clinical study on the significance of platelet-activating factor in the pathophysiology of septic disseminated intravascular coagulation in surgery
171. Chronic intravascular syndromes
172. Turnover of fibrinogen and platelets in dogs undergoing induced intravascular coagulation
173. Acute pancreatitis and deep vein thrombosis associated with the HELLP syndrome
174. The pathophysiology of thrombosis in cancer
175. Determination of human prothrombin activation fragment 1 + 2 in plasma with an antibody against a synthetic peptide
176. Meconium and amniotic fluid embolism: Effects on coagulation in pregnant mini-pigs
177. Amniotic fluid embolism: An analysis of 40 cases
178. Tumors, mucus production, and hypercoagulability
179. The activation of coagulation by extracts of mucin: A possible pathway of intravascular coagulation accompanying adenocarcinomas
180. Surface markers of fibrinogen and its physiologic derivatives related by antibody probes
181. The perinatal outcome in adolescents with eclampsia and the HELLP syndrome
182. HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets) pathophysiology and anesthetic considerations
183. Amniotic fluid embolism three case reports with a review of the literature
184. Studies on the procoagulant activity of human amniotic fluid I. Stability and coagulation factor requirements
185. Studies on the procoagulant activity of human amniotic fluid II. The role of factor VII
186. Aggressive versus conservative management of HELLP syndrome - A status assessment
187. Hemorrhagic states during pregnancy. I
188. Hemorrhagic states during pregnancy
189. Epsilon aminocaproic acid: A dangerous weapon
190. Intravascular clotting and afibrinogenemia the presumptive lethal factors in the syndrome of amniotic fluid embolism
191. Pathology of disseminated intravascular coagulation (DIC). Analysis of 26 cases
192. Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro
193. Bleeding due to increased intravascular blood coagulation: Hemorrhagic syndromes caused by consumption of blood-clotting factors (consumption coagulopathies)
194. Activation of human prothrombin by highly purified human factors V and Xa in the presence of human antithrombin
195. Intravascular coagulation in a case of Clostridium perfringens septicemia: Treatment by exchange transfusion and heparin
196. Amniotic fluid embolism: A review of the syndrome with a report of 4 cases
197. An immunoassay for human D-dimer using monodonal antibodies
198. Pathogenesis of the intravascular coagulation syndrome induced by immunological reactions
199. Markers of intravascular coagulation and fibrinolysis in preeclampsia: Association with intrauterine growth retardation
200. Chronic intravascular coagulation syndrome associated with atherosclerotic aortic aneurysm
201. Interrelationships of the fibrinolytic, coagulation, kiningeneration, and complement systems
202. Factors in the control of bleeding
203. Spontaneous intrahepatic hemorrhage and hepatic rupture in the HELLP syndrome: Four cases and a review
204. Hyaline microthrombi in an autopsy material. A quantitative study with discussion of the relationship to small vessel thrombosis
205. Coagulation profile and ethanol gelation test with special reference to components consumed during coagulation
206. Adult hyaline membrane disease
207. Fibrin degradation products in thromboembolic disease
208. F 1 + 2 and FPA in urine from patients with multiple trauma and healthy individuals: A pilot study
209. Studies to detect the escape of amniotic fluid into the maternal circulation during parturition
210. Amniotic fluid embolism: To understand an enigma
211. Defibrination after intra-amniotic injection of hypertonic saline
212. Consumptive coagulopathy in obstetrics and gynecology
213. Accelerated fibrinogen and platelet destruction after peritoneovenous shunting
214. Maternal pulmonary embolism by amniotic fluid as a cause of shock and unexplained deaths in obstetrics
215. The value of the FM-test (KABI) and thrombin-antithrombin-III complexes (TAT) in the management of DIC in cancer
216. HELLP syndrome: Hemolysis, elevated liver enzymes and low platelets
217. Relation of the fibrinolytic to other biological systems
218. Amniotic fluid embolism: Prophylaxis with heparin and aspirin
219. Erythrocytes and blood coagulation
220. Hypercoagulability and DIC in high-risk infants
221. Excessive fibrinolysis in suspected amyloidosis: Demonstration of plasmin-alpha-2 plasmin inhibitor complex and yon Willebrand factor fragment in plasma
222. Plasmin-alpha-2-plasmin inhibitor complex in plasma of patients with disseminated intravascular coagulation
223. Biology of recombinant hirudin (CG 39393): A new prospect in the treatment of thrombosis
224. Antithrombin deficiency and thromboembolism
225. 1+2 fragment and thrombin-antithrombin complex
226. Clinical studies of the use of fluorogenic substrate assay method for the determination of plasminogen
227. D-dimer in different stages of pregnancy toxemia. A pilot study
228. Diagnosis and treatment of nephrotic syndrome during pregnancy
229. Pulmonary hyaline membranes studied with the electron microscope
230. Inhaled aerosolized prostacyclin as a selective pulmonary vasodilator for the treatment of severe hypoxaemia
231. Role of high molecular weight kininogen in contact activation
232. The effect of amniotic fluid on the human omental artery in vitro
233. Dexamethasone in the post-partum treatment of HELLP syndrome
234. Antithrombin III in shock and disseminated intravascular coagulation
235. Hereditary and acquired antithrombin deficiency
236. Liver rupture in pregnancy: A life-threatening complication of the HELLP syndrome
237. Disseminated intravascular coagulation (DIC) with massive hyperfibrinolysis in metastatic uterine cancer: Observations on the effects on the coagulopathy of various treatments
238. Determination of plasmin-alpha-2-plasmin inhibitor complex in plasma samples by means of a radioimmunoassay
239. Thromboplastic activity in amniotic fluid during pregnancy
240. Thromboplastic activity of amniotic fluid in term and postmature gestations
241. Effects of postpartum corticosteroids in patients with HELLP syndrome
242. Infection and disseminated intravascular coagulation
243. β-thromboglobulin - A specific marker of in vivo platelet release reaction